Call
2 mg perindopril / 0.625 mg indapamide is indicated for the initial treatment of mild to moderate essential hypertension.
4 mg perindopril / 1.25 mg indapamide and 8 mg perindopril / 2.5 mg indapamide) are indicated in the treatment of mild to moderate essential hypertension in patients for whom combination therapy is appropriate.
4 mg perindopril / 1.25 mg indapamide and 8 mg perindopril / 2.5 mg indapamide are not indicated for initial therapy. Patients in whom perindopril and indapamide are initiated simultaneously can develop symptomatic hypotension.
Patients should be titrated on the individual drugs. If the fixed combination represents the dosage determined by this titration, the use of (4 mg perindopril / 1.25 mg indapamide) and (8 mg perindopril / 2.5 mg indapamide) may prove to be more convenient in the management of patients. If during maintenance therapy dosage adjustment is necessary, it is advisable to use individual drugs
The safety and efficacy of perindopril / indapamide in renovascular hypertension and in congestive heart failure have not been established and therefore, their use in this condition is not recommended.
Geriatrics (> 65 years of age): Although the blood pressure response and safety profile of in patients >65 years old were comparable to those of the younger adult patients, greater sensitivity of some elderly patients cannot be ruled out.
Pediatrics: The safety and effectiveness of in children have not been established. Its use in this age group, therefore, is not recommended.
Renal failure:
- Creatinine clearance (CrCl) >30 ml/min: No dosage modification.
- Creatinine clearance (CrCl) <30 ml/min: Treatment contraindicated.
পেরিনডাল ৪ প্লাস ট্যাবলেট সম্পর্কে বিস্তারিত জেনে নিন এই লিঙ্ক থেকে পেরিনডাল ৪ প্লাস
ভিডিও কলে ডাক্তারের পরামর্শ পেতে Play Store থেকে ডাউনলোড করুন Bissoy অ্যাপ